NCT01608737View on ClinicalTrials.gov

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2015

Conditions
Hepatitis C, Chronic
Interventions
DRUG

PegIFN/RBV

PegIFN/RBV for 48 weeks

DRUG

BI 201335

BI 201335 once daily high dose for 12 weeks

DRUG

BI 201335

BI 201335 once daily high dose for 12 weeks

DRUG

PegIFN/RBV

PegIFN/RBV for 48 weeks

DRUG

BI 201335

BI 201335 once daily low dose for 24 weeks

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY